Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | J.S. de Bono, U. De Giorgi, C. Massard, S. Bracarda, D. Nava Rodrigues, I.Kocak, A. Font, J. Arranz Arija, K. Shih, G.D. Radavoi, W. Yu, W. Chan, S. Gendreau, L. Zhang, R. Riisnaes, M.J. Wongchenko, D. Maslyar, V. Jinga | ||||||||||||
Title | PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) | ||||||||||||
|
|||||||||||||
URL | https://academic.oup.com/annonc/article/27/suppl_6/718O/2799456/PTEN-loss-as-a-predictive-biomarker-for-the-Akt | ||||||||||||
Abstract Text | Ann Oncol (2016) 27 (suppl_6): 718O |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PTEN loss | castration-resistant prostate carcinoma | sensitive | Abiraterone + Ipatasertib | Phase II | Actionable | In a Phase II trial, the combination of Ipatasertib (GDC-0068) and Zytiga (abiraterone) resulted in a better progression-free survival in metastatic castration resistant prostate cancer patients with PTEN loss (by IHC) when compared to placebo combined with Zytiga (PMID: 30037818; NCT01485861). | 30037818 detail... |